KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Edwards Lifesciences (EW) Revenue (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Revenue data on record, last reported at $1.6 billion in Q4 2025.

  • For Q4 2025, Revenue rose 13.26% year-over-year to $1.6 billion; the TTM value through Dec 2025 reached $6.1 billion, up 11.55%, while the annual FY2025 figure was $6.1 billion, 11.55% up from the prior year.
  • Revenue reached $1.6 billion in Q4 2025 per EW's latest filing, up from $1.6 billion in the prior quarter.
  • Across five years, Revenue topped out at $1.6 billion in Q4 2025 and bottomed at $429.9 million in Q4 2022.
  • Average Revenue over 5 years is $1.3 billion, with a median of $1.3 billion recorded in 2022.
  • Peak YoY movement for Revenue: tumbled 67.67% in 2022, then skyrocketed 194.58% in 2023.
  • A 5-year view of Revenue shows it stood at $1.3 billion in 2021, then crashed by 67.67% to $429.9 million in 2022, then surged by 194.58% to $1.3 billion in 2023, then rose by 9.43% to $1.4 billion in 2024, then grew by 13.26% to $1.6 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $1.6 billion in Q4 2025, $1.6 billion in Q3 2025, and $1.5 billion in Q2 2025.